Showing results (81-90 of 116) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Journal of Immunological Methods|November 21, 2017
How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturersMichaela Nováková, Hana Glier, Naděžda Brdičková, et al.The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.Cancers|February 15, 2022
Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow PanelsŁukasz Sędek, Juan Flores-Montero, Alita van der Sluijs, et al.Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.Hemasphere|April 14, 2025
Minimal residual disease assessment following CD19-targeted therapy in B-cell precursor acute lymphoblastic leukemia using standardized 12-color flow cytometry: A EuroFlow studyMartijn W C Verbeek, Michaela Reiterová, Anna Laqua, et al.The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyOthman Al-Sawaf, Can Zhang, Tong Lu, et al.Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.Pageof 12